Published in final edited form as:

New Horiz Transl Med. 2015 January ; 2(2): 51–54. doi:10.1016/j.nhtm.2014.12.001.

Accredited translational medicine centre: Human renal fibrotic disease: Translational research at the Center for Cell Biology and Cancer Research (CCBCR), Albany Medical College, Albany, NY

Paul J. Higgins¹, Aamir Shahzad², and Jeffrey Kennedy³

¹Center for Cell Biology & Cancer Research, Albany Medical College, Albany, NY 12208

²European Society for Translational Medicine (EUSTM), Vienna, Austria

³Division of Infectious Disease, Albany Medical College, Albany, NY 12208

Translational Research in the Center for Cell Biology and Cancer Research (CCBCR) at Albany Medical College

Translational medicine, as defined by the European Society for Translational Medicine, is an *interdisciplinary branch of the biomedical field supported by three main pillars: benchside, bedside and community. The goal of TM is to combine advances, expertise and techniques within these pillars to leverage and promote enhancements in prevention, diagnosis and therapies.*

Our program, although relatively small in size, attempts to integrate institutional basic and clinical research focusing on areas in which key questions can be addressed by multidisciplinary teams of basic and clinical scientists. The success of this program relies largely on the development and implementation of specific “tools” including the “Innovation Suite” which is coupled to a software application that facilitates linkage among biomedical investigators. Outlined below is the most prominent translational effort in the Center geared to the discovery of pathways and genes amenable to diagnosis, outcomes predication and therapy of human fibrotic disease.

The Renal Fibrosis Program in the Center for Cell Biology and Cancer Research

Studies conducted in the Center for Cell Biology and Cancer Research (CCBCR) at the Albany Medical College (AMC) integrate the discovery of basic molecular events

© 2014 European Society for Translational Medicine. Published by Elsevier Ltd. All rights reserved.

Correspondence: Dr. Paul J. Higgins, Director, Center for Cell Biology & Cancer Research, Albany Medical College, higginp@mail.amc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

underlying the etiology and progression of human fibrosis with *in vivo* interventional strategies and tissue repair outcomes assessments. This effort, it is expected, will provide the rationale for the clinical adaptation of new and focused therapies directed to the control of pathologically-relevant profibrotic genes. Perhaps the most mature, clinically-relevant, multidisciplinary effort focuses on mechanisms underlying the renal fibrotic response to tissue injury. This program involves an extensive network of collaborating urological surgeons, nephrologists, graduate students, residents, basic scientists and molecular biologists and is built on a highly-collaborative framework that fosters translational interactions (Figure 1).

The Center's faculty is comprised of an interdisciplinary group of scientists with expertise in cell biology, molecular biology, biochemistry and physiology. This diversity is reflected in the combined use of cellular, molecular genetic and mouse modeling approaches to clinically-important issues in human pathophysiology. There is an excellent research infrastructure and a visiting investigator program with an emphasis on both basic and translational science. Graduate students and postdoctoral fellows are exposed to a highly-interactive, clinically-relevant, training environment focused on clarifying cell function in normal and disease states. The translational nature of the research facilitates the application of new findings not only to the field of tissue fibrosis but also to a spectrum of human diseases including cancer, atherosclerosis, arthritis and diabetes.

The Center has been granted 'Standard Translational Medicine Centre Accreditation' and Accreditation as an 'Advanced Translational Medicine Centre for the Renal Fibrosis research' by the European society for the Translational Medicine (EUSTM).

Interstitial fibrosis

Interstitial fibrosis is a common and progressive disorder that frequently culminates in organ failure; current treatments are limited and largely ineffective. The majority of fibrotic diseases are progressive, irreversible and eventually fatal. Extent of tissue involvement is a predictive end-stage pathophysiologic hallmark of chronic vascular, renal, hepatic and pulmonary disease, particularly in the clinical setting of diabetes, hypertension, ischemia, obesity, metabolic syndrome, and chronic injury. Regardless of etiology, elevated TGF- β 1 levels (the predominant driver of the fibrotic response) and transcription of TGF- β 1-responsive genes are linked to the activation of profibrotic signaling pathways. Plasminogen activator inhibitor-1 (PAI-1; SERPINE1), a member of the serine protease inhibitor family and a prominent negative regulator of the plasmin-based pericellular proteolytic cascade, is a major causative factor in several clinically significant fibrotic syndromes and healing anomalies. Increased PAI-1 expression, due to increased TGF- β 1 in the injured tissue, initiates and perpetuates the fibrotic cycle. The need for novel targeted approaches for the treatment of fibrosis highlights the clinical potential in the current probe of molecular mechanisms underlying TGF- β 1-regulated PAI-1 gene control [1–3].

The collective research efforts in the CCBCR resulted in the identification of a novel pathway of TGF- β 1-initiated fibrotic gene expression in an *in vivo* model of renal injury that mimics obstructive uropathy in humans [summarized in 1–4]. While TGF- β 1-induced

SMAD2/3 signaling is a critical event in the progression of chronic kidney disease, the role of non-SMAD mechanisms in the orchestration of fibrotic gene changes remain largely unexplored yet constitute likely targets that could be exploited for clinical gain. TGF- β 1/SMAD3 pathway activation in renal fibrosis (induced by ureteral ligation) correlated with epidermal growth factor receptor^{Y845} (EGFR^{Y845}) and p53^{Ser15} phosphorylation followed by induction of the fibrotic disease causative target genes PAI-1 and connective tissue growth factor (CTGF) prompting an investigation of mechanistic involvement of EGFR and p53 in profibrotic signaling. TGF- β 1 PAI-1, CTGF, p53 and EGFR were found to be co-expressed in the obstructed kidney localizing predominantly to the tubular and interstitial compartments and TGF- β 1 activated EGFR, p53 and SMAD2/3. Genetic deficiency of either EGFR or p53 or functional blockade of EGFR kinase activity or p53 signaling with AG1478 or Pifithrin- α , respectively, effectively inhibited PAI-1 and CTGF induction as did SMAD3 knockdown or pretreatment with the SMAD3 inhibitor SIS3. These results provided the first insight as to pharmacologic interventions with clinical potential in the therapy of renal fibrosis that focused on specific pathways involved in controls on disease-critical genes. Reactive oxygen species (ROS)-dependent mechanisms initiated by TGF- β 1 were similarly determined to be critical for EGFR^{Y845} and p53^{Ser15} phosphorylation and target gene expression. The p22^{Phox} subunit of NADPH oxidase was elevated in the fibrotic kidney with an expression pattern similar to p53 and EGFR. This has important translational implications as several inhibitors of ROS generation that block TGF- β 1-induced PAI-1 transcription are already in clinical trials.

These data (**summarized in** Figure 2) highlight the extensive cross-talk among SMAD2/3, EGFR and p53 pathways essential for expression of TGF- β 1-induced fibrotic genes. The additional clinical impact of this work resulted from the subsequent discovery of the involvement of ATM, an upstream activator of p53, in the TGF- β 1 pathway related to renal fibrosis. ATM activation (pATM^{Ser1981}) increased 4-fold in the tubulointerstitial region of the obstructed UUO-injured kidney in mice correlating with SMAD3 and p53^{Ser15} phosphorylation and elevated levels of p22^{phox} subunit of the NADP(H) oxidases and increases in the fibrotic markers PAI-1 and fibronectin. ATM is rapidly phosphorylated at Ser¹⁹⁸¹ by TGF- β 1 stimulation. Stable silencing or pharmacological inhibition of ATM significantly attenuated TGF- β 1-induced p53 activation and subsequent PAI-1, fibronectin, CTGF and p21 expression in renal tubular epithelial cells and fibroblasts. ATM or p53 depletion in renal epithelial cells, moreover, bypassed TGF- β 1-mediated cytostasis while stable silencing of NADPH oxidase (NOX) subunits, p22^{phox} and p47^{phox} blocked TGF- β 1-induced pATM^{Ser1981} and target gene induction via p53-dependent mechanisms.

TGF- β 1, thus, promotes NOX-dependent ATM activation leading to p53-mediated fibrotic gene reprogramming and growth arrest in renal proximal tubular cells. TGF- β 1/ATM-initiated paracrine factor secretion by dysfunctional renal epithelium also promotes interstitial fibroblast growth, suggesting a role of tubular ATM in mediating epithelial-mesenchymal crosstalk highlighting the translational benefit of targeting the NOX/ATM/p53 axis in renal fibrosis [6].

Collectively, this work represents a close and productive collaboration between basic and clinical scientists in the Center for Cell Biology & Cancer Research at Albany Medical

College. This effort has resulted in the identification of translationally-relevant, pharmacologically-manipulatable, targets with potential utility in the therapy of human renal fibrotic disease.

Clinical application of this work has been extended across three additional related lines of human fibrosis. In collaboration with Urological Surgery there is an effort to apply these findings to transitional cell bladder cancer as well as renal and prostate malignancies to determine whether the biological responses identified in the renal injury model might provide universal biomarkers of disease progression or response to conventional therapy at other organ sites. A second line of research involves investigators with expertise in Vascular Surgery to obtain human specimens and develop mouse models to assess the role of this defined pathway (Figure 2) in vaso-occlusive disease. Finally, interstitial lung disease offers a unique human model to validate our tissue and animal data in a prominent pathophysiologic context. Our pulmonary division operates a large Scleroderma clinic providing an opportunity to not only collect patient samples but to correlate findings throughout the natural progression of disease and during the initiation of novel therapies to delay lung fibrosis. Current collaborations with pulmonary research centers in the US and Canada provide opportunities and model systems that are likely to result in clarification of the general applicability of these findings in the broader context of human fibrotic disorders.

Acknowledgments

Supported by NIH grant GM057242 and a grant from the Graver Family Foundation to PJH.

References

1. Overstreet JM, Samarakoon R, Meldrum KK, Higgins PJ. Redox control of p53 in the transcriptional regulation of TGF- β 1 target genes through SMAD cooperativity. *Cell Signal*. 2014; 26:1427–1436. [PubMed: 24613410]
2. Samarakoon R, Dobberfuhl AD, Cooley C, Overstreet JM, Patel S, Goldschmeding R, Meldrum KK, Higgins PJ. Induction of renal fibrotic genes by TGF- β 1 requires EGFR activation, p53 and reactive oxygen species. *Cell Signal*. 2013; 25:2198–2209. [PubMed: 23872073]
3. Samarakoon R, Overstreet JM, Higgins PJ. TGF- β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. *Cell Signal*. 2013; 25:264–268. [PubMed: 23063463]
4. Overstreet JM, Samarakoon R, Cardona-Grau D, Goldschmeding R, Higgins PJ. Tumor Suppressor ATM Functions Downstream of TGF- β 1 in Orchestrating Pro-Fibrotic Responses. *FASEB J*. accepted for publication.

Figure 1.
Translational medicine (TM) model at AMC
SAB=Scientific Advisory Board.

Figure 2. Model of fibrotic gene regulation

TGF-β1 ligand-binding initiates signaling events resulting in the activation of SMAD2/3/4 (canonical pathway). In a collateral (non-canonical) pathway, TGF-β utilizes the p47^{phox} and p22^{phox}-dependent NADPH oxidases to generate ROS necessary for ATM activation as well as its downstream substrate p53. p53 and SMAD, in turn, form a complex that binds to TGF-β target gene promoters (e.g., PAI-1), likely in cooperation with members of the upstream stimulatory factor family (e.g., USF2) of helix-loop-helix transcription factors to stimulate optimal gene expression. Other ROS-dependent non-SMAD elements, including c-src/

EGFR/MAPK, function to recruit additional transcriptional elements as part of a highly-interactive canonical and non-canonical expression control network [adapted from 6].